Impax Laboratories, Inc. (NASDAQ:IPXL) Files An 8-K Submission of Matters to a Vote of Security Holders

Impax Laboratories, Inc. (NASDAQ:IPXL) Files An 8-K Submission of Matters to a Vote of Security Holders

Story continues below

Item 5.07. Submission of Matters to a Vote of Security Holders.

Impax Laboratories, Inc. (the Company) held its 2017 Annual
Meeting of Stockholders on May 16, 2017. The final results of the
voting for each matter submitted to a vote of stockholders at the
meeting are as follows:
Proposal 1: Election of Directors
Each of the following nine nominees for director was elected to
serve a term of one year and until his or her successor has been
elected and qualified or until the directors earlier death,
resignation or removal or service as a director otherwise
concludes.
Nominee
Votes For
Against
Abstentions
Broker Non-Votes
Leslie Z. Benet, Ph.D.
52,569,502
483,600
903,497
7,714,212
Richard A. Bierly
52,672,895
164,483
1,119,221
7,714,212
Paul M. Bisaro
51,960,297
1,039,297
957,005
7,714,212
J. Kevin Buchi
52,810,869
210,492
935,238
7,714,212
Robert L. Burr
49,299,419
3,621,010
1,036,170
7,714,212
Allen Chao, Ph.D.
49,137,892
3,799,919
1,018,788
7,714,212
Mary K. Pendergast, J.D.
49,206,608
3,718,205
1,031,786
7,714,212
Peter R. Terreri
49,093,330
3,853,424
1,009,845
7,714,212
Janet S. Vergis
52,586,198
291,123
1,079,278
7,714,212
Proposal 2: Amendment and Restatement of the Companys Employee
Stock Purchase Plan
The resolution to approve the Amendment and Restatement of the
Companys Non-Qualified Employee Stock Purchase Plan to, among
other items, increase the aggregate number of shares of the
Companys common stock that may be reserved under such plan by
1,500,000 shares was approved.
Votes For
Votes Against
Abstentions
Broker Non-Votes
52,722,477
197,943
1,036,179
7,714,212
Proposal 3: Fourth Amendment and Restatement of the Companys 2002
Equity Incentive Plan
The resolution to approve the Fourth Amendment and Restatement of
the Companys 2002 Equity Incentive Plan to, among other items,
increase the aggregate number of shares of the Companys common
stock that may be issued under such plan by 2,100,000 shares was
approved.
Votes For
Votes Against
Abstentions
Broker Non-Votes
48,079,359
1,496,982
4,380,258
7,714,212
Proposal 4: Advisory Vote on Executive Compensation
The resolution to approve, on a non-binding advisory basis, the
compensation of the Companys named executive officers was
approved.
Votes For
Votes Against
Abstentions
Broker Non-Votes
51,538,733
1,335,218
1,082,648
7,714,212
Proposal 5: Advisory Vote on Frequency of Say-on-Pay Vote
The resolution to approve, on a non-binding advisory basis, the
frequency of named executive officer compensation votes of one
year is approved.
One Year
Two Years
Three Years
Abstentions
Broker Non-Votes
39,946,915
103,805
12,872,721
1,033,158
7,714,212
Proposal 6: Ratification of Appointment of Independent Registered
Public Accounting Firm
KPMG LLP was ratified as the Companys independent registered
public accounting firm for the fiscal year ending December 31,
2017. >
Votes For
Votes Against
Abstentions
Broker Non-Votes
60,021,800
296,512
1,352,499
_


About Impax Laboratories, Inc. (NASDAQ:IPXL)

Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), as well as the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of various branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.

Impax Laboratories, Inc. (NASDAQ:IPXL) Recent Trading Information

Impax Laboratories, Inc. (NASDAQ:IPXL) closed its last trading session down -0.30 at 16.10 with 1,448,637 shares trading hands.

An ad to help with our costs